Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions

NCT03113942 is registered in ClinicalTrials.gov with Kirby Institute as lead sponsor.

NCT NCT03113942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03113942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions
Lead sponsor
Kirby Institute
Phase
Phase 2
Overall status
Unknown status
Start date
June 14, 2017
Completion date
December 31, 2022
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high grade squamous intra-epithelial lesion (hsil)